Cargando…
Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal
SIMPLE SUMMARY: Relapse is still a major problem in AML because it occurs in about 60–80% of patients, even those who have previously achieved complete remission (CR), defined by the presence of ≤5% bone marrow (BM) leukemic cells. Thus, since CR is unable to predict the relapse risk, significantly...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268140/ https://www.ncbi.nlm.nih.gov/pubmed/34202000 http://dx.doi.org/10.3390/cancers13133170 |